公开(公告)号：US20190315754A1

公开(公告)日：2019-10-17

申请号：US16391882

申请日：2019-04-23

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Wanjun Zheng ,  Xiaojie Zhu ,  Hong Du ,  Maarten Postema ,  Yimin Jiang ,  Jing Li ,  Robert Yu ,  Hyeong-wook Choi ,  Jaemoon Lee ,  Frank Fang ,  Daniel Custar

IPC: C07D487/04 ,  C07D519/00 ,  A61P35/00

Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.

公开(公告)号：USRE47797E1

公开(公告)日：2020-01-07

申请号：US15944480

申请日：2018-04-03

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Farid Benayoud ,  Trevor Lee Calkins ,  Charles E. Chase ,  William Christ ,  Bryan M. Lewis ,  Matthew Schnaderbeck ,  Marc Pesant ,  Brian Austad ,  Silvio Campagna ,  Yongbo Hu ,  Gordon Wilkie ,  Xiaojie Zhu ,  Francis G. Fang

IPC: C07D307/28 ,  C07F7/18 ,  C07C33/42 ,  C07D407/06 ,  C07D407/14 ,  C07D493/04 ,  C07D493/08 ,  C07D493/18 ,  C07D493/22 ,  C07D493/20 ,  C07D317/72 ,  C07H15/26 ,  A61K31/341 ,  C07D307/12 ,  C07D493/10 ,  C07D307/33

Abstract: Intermediates and methods of their use in the synthesis of analogs of halichondrin B are provided.

公开(公告)号：US11434246B2

公开(公告)日：2022-09-06

申请号：US17141557

申请日：2021-01-05

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Wanjun Zheng ,  Xiaojie Zhu ,  Hong Du ,  Maarten Postema ,  Yimin Jiang ,  Jing Li ,  Robert Yu ,  Hyeong-Wook Choi ,  Jaemoon Lee ,  Francis G. Fang ,  Daniel Custar

IPC: C07D487/04 ,  C07D519/00 ,  A61P35/00

Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.

公开(公告)号：US10941148B2

公开(公告)日：2021-03-09

申请号：US16391882

申请日：2019-04-23

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Wanjun Zheng ,  Xiaojie Zhu ,  Hong Du ,  Maarten Postema ,  Yimin Jiang ,  Jing Li ,  Robert Yu ,  Hyeong-wook Choi ,  Jaemoon Lee ,  Frank Fang ,  Daniel Custar

IPC: C07D487/04 ,  C07D519/00 ,  A61P35/00

Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.

公开(公告)号：US20180305362A1

公开(公告)日：2018-10-25

申请号：US15768668

申请日：2016-10-14

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Wanjun Zheng ,  Xiaojie Zhu ,  Hong Du ,  Maarten Postema ,  Yimin Jiang ,  Jing Li ,  Robert Yu ,  Hyeong-wook Choi ,  Jaemoon Lee ,  Frank Fang ,  Daniel Custar

IPC: C07D487/04 ,  C07D519/00 ,  A61P35/00

CPC classification number: C07D487/04 ,  A61P35/00 ,  C07D519/00

Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.

公开(公告)号：US10316040B2

公开(公告)日：2019-06-11

申请号：US15768668

申请日：2016-10-14

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Wanjun Zheng ,  Xiaojie Zhu ,  Hong Du ,  Maarten Postema ,  Yimin Jiang ,  Jing Li ,  Robert Yu ,  Hyeong-wook Choi ,  Jaemoon Lee ,  Frank Fang ,  Daniel Custar

IPC: C07D487/04 ,  C07D519/00 ,  A61P35/00

Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.